Navignostics has been honored with the prestigious Swiss Tech Award in the Start-ups (Rising Stars) category, recognizing the company's pioneering work in precision oncology.
The award celebrates Navignostics’ innovative approach to cancer treatment through spatial single-cell proteomics technology, which enables detailed analysis of tumour and immune cells directly within tissue samples. This cutting-edge methodology allows clinicians to understand the composition, interactions, and resistance mechanisms of cancer cells at an unprecedented level of detail, paving the way for truly personalized therapy decisions.
The Swiss Tech Award jury was particularly impressed by the company’s sharp focus on clinical application. “Navignostics has developed a solution with a razor-sharp scope,” the jury noted, highlighting how the technology is specifically designed to support tumour boards in selecting optimal therapies for late-stage cancer patients – a critical need in oncology where treatment decisions can significantly impact patient outcomes.
Beyond the innovative technology itself, the jury recognized Navignostics’ solid scientific foundation, technical excellence, and well-developed business strategy, including proven market validation and initial commercial traction.
This recognition underscores Navignostics’ position at the forefront of Swiss medtech innovation and reinforces our commitment to transforming cancer care through precision diagnostics.
About the Swiss Tech Award
The Swiss Tech Award recognizes exceptional Swiss technology companies and innovations. The Rising Stars category honors start-ups that have moved beyond the concept stage with functioning prototypes, validated market feedback, and solid business foundations.
